Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group

BACKGROUND: Sequential anthracyclines and taxanes are standard adjuvant chemotherapy for patients with high-risk axillary node-positive breast cancer. We compared a sequential to a concurrent regimen in high-risk node-negative early breast cancer. METHODS: Patients were eligible if they had tumours...

Descripción completa

Detalles Bibliográficos
Autores principales: Mavroudis, Dimitrios, Saloustros, Emmanouil, Boukovinas, Ioannis, Papakotoulas, Pavlos, Kakolyris, Stylianos, Ziras, Nikolaos, Christophylakis, Charalampos, Kentepozidis, Nikolaos, Fountzilas, Georgios, Rigas, Georgios, Varthalitis, Ioannis, Kalbakis, Konstantinos, Agelaki, Sofia, Hatzidaki, Dora, Georgoulias, Vasilios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584474/
https://www.ncbi.nlm.nih.gov/pubmed/28641315
http://dx.doi.org/10.1038/bjc.2017.158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584474/
https://www.ncbi.nlm.nih.gov/pubmed/28641315
http://dx.doi.org/10.1038/bjc.2017.158

Ejemplares similares